Vivitrol | Addiction Professional Magazine Skip to content Skip to navigation

Vivitrol

FDA approves non-opioid for opioid withdrawal symptoms

May 17, 2018  |  Gary A. Enos, Editor
news
The Food and Drug Administration has approved the first non-opioid medication for the treatment of painful opioid withdrawal symptoms.

Separate unit for opioid disorder treatment builds fellowship

May 7, 2018  |  Gary A. Enos, Editor
article
Caron Treatment Centers responded to patient concerns about isolation by establishing a treatment unit devoted exclusively to opioid use disorders.

Study explores challenge of initiating patient on injectable naltrexone

April 17, 2018  |  Gary A. Enos, Editor
article
New research offers hope for those who might assume it is too difficult to transition an opioid-dependent patient to injectable naltrexone in a community-based setting.

First non-opioid to treat withdrawal clears key hurdle

April 13, 2018  |  Alison Knopf, Contributing Writer
article
An advisory committee to the Food and Drug Administration (FDA) is recommending approval of lofexidine, which would offer an alternative to opioid medications for treatment of opioid withdrawal symptoms.

SCE: Be open to evidence-based treatment

March 9, 2018  |  Julie Miller, Editor in Chief
article
Experts speaking in Chicago at the Summit For Clinical Excellence, The Opioid Crisis: Strategies for Treatment and Recovery covered a number of treatment modalities that clinicians might not be embracing just yet.

Study offers reasons why alcohol medication adherence poses challenge

February 15, 2018  |  Gary A. Enos, Editor
article
Research reveals several factors that influence the ability of patients with an alcohol use disorder to stay on a daily medication regimen, including intense cravings and a weekend danger.

Drug studies' results make case for access to all opioid dependence medications

November 16, 2017  |  Gary A. Enos, Editor
article
Recent efficacy and safety studies found comparable and encouraging results for buprenorphine and injectable naltrexone in the treatment of opioid dependence.

FDA clears electrical device to combat opioid withdrawal

November 15, 2017  |  Gary A. Enos, Editor
news
The Food and Drug Administration (FDA) today announced that an electrical stimulation device attached to the ear can be marketed for the treatment of symptoms of opioid withdrawal.

Hospital boosts opioid patients' rapid access to medication

November 14, 2017  |  Gary A. Enos, Editor
article
The experience of Boston Medical Center bolsters evidence that hospitalized patients with opioid use disorders can be successfully initiated on medication before discharge.

Opioid treatment programs growing, and expanding into other medications

August 23, 2017  |  Gary A. Enos, Editor
news
Today's opioid treatment programs (OTPs) are increasingly likely to be offering buprenorphine and injectable naltrexone treatment in addition to methadone.

NCAD: Doctor attacks misconceptions about opioid addiction medications

August 20, 2017  |  Gary A. Enos, Editor
article
The owner of Addiction Recovery Resources in Louisiana discussed why it makes sense to integrate 12-Step and medication approaches to opioid addiction treatment.

Could a device attached to the ear become a game-changer in detox?

April 12, 2017  |  Gary A. Enos, Editor
article
An electrical stimulation device that is approved for pain is gaining use as a method of easing withdrawal from opioids and facilitating access to longer-term treatment.

Pages

Subscribe to Vivitrol